Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Carney

Showing results (271-280 of 275) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 275 results.
Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAKShiela C Samson, Anthony Rojas, Rebecca G Zitnay, et al.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Journal of Addiction Psychiatry|September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and PresentKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Research Square|December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis MedicinalsKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Pageof 28

Showing results (271-280 of 275) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 275 results.
Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAKShiela C Samson, Anthony Rojas, Rebecca G Zitnay, et al.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Journal of Addiction Psychiatry|September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and PresentKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Research Square|December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis MedicinalsKenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Pageof 28